Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
0.3561
Dollar change
+0.0072
Percentage change
2.06
%
Index- P/E- EPS (ttm)-0.21 Insider Own8.30% Shs Outstand760.05M Perf Week1.74%
Market Cap270.65M Forward P/E- EPS next Y-0.10 Insider Trans0.00% Shs Float696.93M Perf Month2.92%
Income-52.08M PEG- EPS next Q-0.03 Inst Own41.55% Short Float3.24% Perf Quarter1.71%
Sales0.00M P/S- EPS this Y12.61% Inst Trans- Short Ratio4.38 Perf Half Y-22.54%
Book/sh0.22 P/B1.59 EPS next Y38.67% ROA-72.76% Short Interest22.57M Perf Year22.84%
Cash/sh0.04 P/C9.15 EPS next 5Y- ROE-78.03% 52W Range0.21 - 0.74 Perf YTD-13.15%
Dividend Est.- P/FCF- EPS past 5Y-68.39% ROI-56.64% 52W High-51.75% Beta-
Dividend TTM- Quick Ratio5.76 Sales past 5Y-20.00% Gross Margin- 52W Low69.57% ATR (14)0.02
Dividend Ex-Date- Current Ratio5.76 EPS Y/Y TTM7.00% Oper. Margin0.00% RSI (14)47.11 Volatility4.28% 4.58%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-59.19% Payout- Rel Volume0.45 Prev Close0.35
Sales Surprise- EPS Surprise-110.79% Sales Q/Q- EarningsFeb 14 BMO Avg Volume5.15M Price0.36
SMA200.37% SMA50-7.53% SMA200-13.57% Trades Volume2,307,671 Change2.06%
Date Action Analyst Rating Change Price Target Change
Nov-19-21Downgrade Maxim Group Buy → Hold
May-14-24 07:30AM
May-06-24 08:32AM
Apr-25-24 07:30AM
Apr-18-24 07:30AM
Apr-16-24 07:30AM
07:30AM Loading…
Apr-10-24 07:30AM
Mar-19-24 11:53AM
Mar-18-24 07:30AM
Mar-15-24 07:30AM
Mar-14-24 07:30AM
Mar-13-24 07:00AM
06:00AM
Mar-12-24 10:37PM
Feb-27-24 07:30AM
Feb-14-24 07:45AM
07:30AM Loading…
Feb-07-24 07:30AM
Jan-28-24 05:02PM
Jan-24-24 09:00AM
Jan-23-24 07:30AM
Jan-08-24 07:34AM
Jan-04-24 07:32AM
Dec-06-23 07:30AM
Dec-05-23 07:30AM
Nov-30-23 07:30AM
Nov-20-23 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-14-23 07:16PM
01:00PM
Nov-10-23 08:13AM
08:05AM Loading…
08:05AM
08:03AM
Nov-03-23 07:40AM
Nov-01-23 03:32PM
07:30AM
Oct-31-23 09:00AM
07:45AM
Oct-29-23 05:17PM
Oct-26-23 07:30AM
Oct-25-23 07:30AM
Oct-23-23 07:33AM
Oct-17-23 05:35PM
Oct-12-23 05:00PM
Oct-06-23 07:30AM
Oct-04-23 07:30AM
Oct-03-23 07:30AM
Sep-27-23 07:30AM
Sep-26-23 07:30AM
Sep-25-23 07:30AM
Sep-21-23 05:00PM
07:30AM
Sep-05-23 07:30AM
Aug-28-23 01:23PM
10:57AM
09:22AM
Aug-23-23 09:37PM
Aug-21-23 01:40PM
Aug-17-23 07:30AM
Aug-15-23 07:52AM
Aug-14-23 07:30AM
Aug-04-23 09:46AM
Aug-02-23 07:30AM
Aug-01-23 09:32AM
Jul-31-23 06:29PM
Jul-27-23 07:30AM
Jul-26-23 07:30AM
Jul-24-23 07:55AM
Jul-20-23 05:01PM
08:00AM
Jul-17-23 08:44AM
Jul-12-23 07:30AM
Jun-30-23 07:30AM
Jun-29-23 05:00PM
Jun-27-23 05:00PM
07:30AM
Jun-21-23 07:30AM
Jun-15-23 07:30AM
Jun-08-23 07:30AM
Jun-05-23 07:30AM
Jun-01-23 07:30AM
May-30-23 05:46PM
May-24-23 07:30AM
May-09-23 07:30AM
Apr-28-23 08:00AM
Apr-12-23 07:30AM
Mar-08-23 07:30AM
Mar-02-23 04:23PM
Feb-28-23 07:30AM
Feb-22-23 04:30PM
Feb-14-23 07:30AM
Feb-01-23 07:30AM
Jan-26-23 07:30AM
Jan-23-23 09:33PM
Jan-18-23 07:30AM
Jan-17-23 05:00AM
Jan-12-23 07:30AM
Jan-08-23 05:00PM
Dec-20-22 08:00AM
Dec-06-22 04:01PM
Nov-15-22 08:00AM
Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.